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Sexual transmission of HIV-1 is an inefficient process, with only one
or few variants of the donor quasispecies establishing the new
infection. A critical, and as yet unresolved, question is whether the
mucosal bottleneck selects for viruses with increased transmission
fitness. Here, we characterized 300 limiting dilution-derived virus
isolates from the plasma, and in some instances genital secretions,
of eight HIV-1 donor and recipient pairs. Although there were no
differences in the amount of virion-associated envelope glycopro-
tein, recipient isolates were on average threefold more infectious
(P = 0.0001), replicated to 1.4-fold higher titers (P = 0.004), were
released from infected cells 4.2-fold more efficiently (P < 0.00001),
and were significantly more resistant to type I IFNs than the corre-
sponding donor isolates. Remarkably, transmitted viruses exhibited
7.8-fold higher IFNα2 (P < 0.00001) and 39-fold higher IFNβ (P <
0.00001) half-maximal inhibitory concentrations (IC50) than did do-
nor isolates, and their odds of replicating in CD4+ T cells at the
highest IFNα2 and IFNβ doses were 35-fold (P < 0.00001) and
250-fold (P < 0.00001) greater, respectively. Interestingly, pretreat-
ment of CD4+ T cells with IFNβ, but not IFNα2, selected donor
plasma isolates that exhibited a transmitted virus-like phenotype,
and such viruses were also detected in the donor genital tract. These
data indicate that transmitted viruses are phenotypically distinct,
and that increased IFN resistance represents their most distinguish-
ing property. Thus, the mucosal bottleneck selects for viruses that
are able to replicate and spread efficiently in the face of a potent
innate immune response.
mucosal HIV-1 transmission | type I interferons | innate immunity |
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Understanding the host and viral factors that influence HIV-1transmission may aid the development of an effective AIDS
vaccine. In 2015, ∼2 million individuals were newly infected with
HIV-1, the great majority of whom acquired the virus by sexual
routes (1). Although a number of factors, such as high donor viral
loads, genital inflammation, altered mucosal microbiota, and re-
cipient gender, are known to increase the infection risk (2–4), virus
transmission across intact mucosal surfaces is inherently inefficient,
with only a small fraction (less than 1%) of unprotected sexual ex-
posures leading to productive infection (5–8). This inefficiency is
exemplified by a stringent population bottleneck, in which only one
or a limited number of variants from the diverse quasispecies of the
transmitting donor establish the new infection (9). Transmitted
viruses are not usually the most abundant strains in the genital se-
cretions of infected donors (10), and analyses of viral sequences from
137 matched donor and recipient pairs indicated that viruses with a
more ancestral genotype are preferentially transmitted (11). These
data suggested that mucosal transmission selects for variants with
enhanced transmission fitness (11). However, the viral properties
that contribute to this transmission fitness have not been defined.
For obvious reasons, viruses cannot be collected from, or
studied in, humans at the time of transmission. However, by
sequencing plasma virion RNA (vRNA) in the first few weeks
following transmission, it is possible to enumerate and infer
the genome(s) of the virus(es) that established the infection (9,
12–14). In the absence of adaptive immune pressures, HIV-1
diversifies in a random fashion, with viral sequences exhibiting a
Poisson distribution of mutations and a star-like phylogeny that
coalesces to an inferred consensus sequence. This consensus
sequence represents the genome of the virus that initiated the
infection, termed the transmitted founder (TF) virus (9). Single
genome amplification (SGA) of plasma vRNA, which precludes
PCR artifacts such as Taq polymerase-mediated recombination
(15–18), revealed that in the great majority (∼80%) of sexual
transmission cases, a single TF virus establishes the new infection
(9, 12, 13, 19–21).
The ability to infer and molecularly clone the genomes of TF
viruses has permitted their biological characterization. Initial
studies showed that TF viruses use the cell-surface molecules CD4
and CCR5 as their receptor and coreceptor, and replicate efficiently
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in activated CD4+ T cells but not macrophages (14, 22–25).
Moreover, analysis of a comprehensive panel of infectious molec-
ular clones (IMCs) showed that TF viruses packaged more envelope
glycoprotein (Env), exhibited greater infectivity, bound to mono-
cyte-derived dendritic cells more efficiently, and replicated to higher
titers in CD4+ T cells in the presence of the type 1 interferon IFNα2
than chronic control (CC) viruses (26). However, a potential con-
founder of these studies was the fact that TF and CC viruses were
not derived from epidemiologically linked transmission pairs. To
compare transmitted and nontransmitted viruses close to the time
of transmission, two recent studies characterized the phenotype
of viruses from matched donor and recipient pairs (27, 28).
Examining various biological properties, including the sensi-
tivity of donor and recipient viruses to IFNα2, both studies
failed to identify viral traits that were indicative of enhanced
transmission fitness (27, 28).
Innate immune responses, in particular type 1 IFNs, rep-
resent a potent first-line defense against many pathogens,
including primate lentiviruses (29–33). Consistent with these data,
treatment of rhesus macaques with pegylated IFNα2 increased the
number of intrarectal challenges required to achieve systemic
simian immunodeficiency virus (SIV) infection and decreased the
number of transmitted founder viruses (34). Similarly, mucosal
application of IFNβ protected macaques from repeated intrarectal
and intravaginal challenges with a simian–human immunodefi-
ciency virus (SHIV) (35). Because type 1 IFNs are rapidly up-
regulated at mucosal sites of virus replication in SIV-infected
macaques (36), and bioactive IFN levels are highly elevated
during acute HIV-1 infection (37), we hypothesized that IFN-
mediated antiviral activity contributes to the HIV-1 transmission
bottleneck. To test this hypothesis, we generated a large panel of
limiting dilution-derived isolates from the plasma and genital
secretions of chronically infected donors and their matched
recipients. Analyzing 300 such isolates, we identified a number of
biological properties that are associated with increased trans-
mission fitness, all of which serve to enhance HIV-1 replication
and spread in the face of a vigorous innate immune response.
Results
Generation of Limiting Dilution HIV-1 Isolates from Sexual Transmission
Pairs. Molecular cloning of HIV-1 genomes is labor intensive and
thus limits the number of IMCs that can reasonably be charac-
terized. Moreover, predicting which viral genomes are functional
in chronically infected individuals is challenging, because immune
escape mutations frequently incur fitness costs (38–45). Virus
isolation represents an alternative to cloning, but bulk cultures
cannot account for the biological variation of individual quasis-
pecies members. Here, we used limiting dilution virus isolation to
generate single virion-derived HIV-1 strains from eight sexual
transmission pairs. These included four female-to-male (FTM)
transmissions (subtype C) from southern Africa as well as from
one male-to-female (MTF) and three men-who-have-sex-with-
men (MSM) transmissions (subtype B) from the United States (SI
Appendix, Table S1). In all but one case, the newly infected re-
cipient was identified first as part of an acute infection cohort,
whereas the transmitting partner was identified retrospectively.
Phylogenetic analysis of SGA-derived plasma viral sequences
confirmed that all transmission pairs were epidemiologically
linked (SI Appendix, Fig. S1) and showed that two recipients
(CH378 and CH831) had acquired their infection from the same
donor (CH742). Seven of the eight recipients were infected with a
single TF virus, whereas the remaining subject (CH378) acquired
at least two TF viruses (SI Appendix, Fig. S2). All subjects
remained treatment naïve throughout the study.
To generate limiting dilution-derived viral isolates, plasma as
well as cell-free fractions of cervicovaginal lavage (CVL) and se-
men (SEM) samples were end-point diluted and used to infect
activated normal donor CD4+ T cells in 24-well plates. According
to a Poisson distribution, a dilution that yields positive cultures in
no more than 30% of wells should contain a single infectious unit
more than 80% of the time. Cultures were maintained for 20 d,
tested for p24 antigen production, and virus positive wells were
expanded further in normal donor CD4+ T cells for an additional
10 d. The resulting viral stocks were used for all subsequent ge-
netic and biological analyses.
To ensure that the limiting dilution isolates were indeed single
virion derived, we sequenced all stocks before biological charac-
terization. Briefly, 5′ and 3′ half genomes were PCR amplified,
MiSeq sequenced, and the resulting reads assembled to generate
an isolate-specific consensus sequence. Viral reads were then
mapped to this consensus sequence and the extent of genetic di-
versity was examined for each position along the genome. Isolates
that exhibited more than 15% diversity at any one position in the
alignment were considered to contain more than one variant and
thus removed from further analysis. To control for the emergence
of phenotypically distinct variants in the culture, we also generated
limiting dilution isolates from all acutely infected subjects even
though TF IMCs were available for two recipients (14, 26). Using
plasma samples collected closest to the time of transmission, we
generated 95 donor and 61 recipient isolates (SI Appendix, Table
S1). Virus isolation from CVL and SEM samples was more chal-
lenging, because of lower viral loads, frequent bacterial and yeast
contaminations, and the fact that many genital secretions were
inherently cytotoxic for CD4+ T cells (46). Nonetheless, we were
able to generate limiting dilution isolates from the CVL or semen
samples of three transmitting donors (SI Appendix, Table S1).
Limiting Dilution HIV-1 Isolates Are Representative of the Donor
Quasispecies. To determine whether the limiting dilution iso-
lates were representative of the viral quasispecies present in both
donors and recipients, we compared all isolate-derived se-
quences to SGA-derived vRNA sequences amplified directly
from the blood of the same individual. In phylogenetic trees of 3′
half genome sequences, isolate and plasma vRNA sequences
were completely interspersed (Fig. 1A and SI Appendix, Fig. S3).
To assess whether isolate and plasma viral sequences from
chronically infected donors were segregated, we calculated their
genealogical sorting index (gsi) (47). Two donor samples yielded
gsi values that were higher than expected from random segre-
gation (SI Appendix, Table S2A). In one case (CH212), available
isolates represented only two of three diverse viral lineages
present in this donor’s quasispecies, indicating limited sampling
(SI Appendix, Fig. S3F). In the other case (CH728), two pairs of
near identical isolate sequences indicated repeat culture of the
same virus (SI Appendix, Fig. S3C). Collapsing one of these to a
single sequence rendered the gsi value nonsignificant. For all
other subjects, there was no evidence for segregation (SI Ap-
pendix, Table S2A), indicating that the isolates were fully rep-
resentative of the viral diversity present in the plasma. As
expected, plasma isolates from single TF infections were very
closely related, differing from each other by fewer than 8 (range
2–7) and from the inferred TF genome by fewer than 12 (range
2–11) nucleotides across the entire genome (SI Appendix, Fig.
S2). Plasma isolates from subject CH378 exhibited greater di-
versity, because they represented the progeny of two TF viruses
as well as their recombinants (SI Appendix, Fig. S2A). Unlike in
some previous studies (8), there was no evidence of compart-
mentalization of plasma and genital secretion isolates from do-
nors CH492 and CH742 (SI Appendix, Fig. S3 and Table S2B).
Increased Env Content Is Not a Characteristic Feature of Transmitted
Viruses. Comparing viruses from unrelated subjects, we pre-
viously reported that TF IMCs package on average 1.9-fold more
Env than viruses circulating in the plasma of chronically infected
individuals (26). To examine the Env content of matched donor
and recipient isolates, we generated viral stocks in normal donor
CD4+ T cells, depleted these of microvesicles, purified virions
using antibody-coated magnetic beads, and quantified Env by
ELISA per unit of RT activity. We found that plasma isolates
varied widely in the amounts of Env that they packaged, but
failed to identify consistent differences between donor and re-
cipient isolates. Recipient isolates packaged either significantly
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more, less, or similar amounts of Env compared with their cor-
responding donor viruses (Fig. 1B and SI Appendix, Fig. S4A).
For one donor (CH492), genital tract isolates had a 2.4-fold
higher mean Env content than the corresponding plasma iso-
lates, but this was not the case for the other two donors (Fig. 1B
and SI Appendix, Fig. S4A). When data from all pairs were
combined, no significant differences in Env content were ob-
served between donor and recipient isolates, plasma and genital
secretion isolates, and subtype B and C recipient isolates (Fig.
1C). These data indicate that mucosal transmission does not
select for viruses with an increased Env content.
Transmitted Viruses Exhibit Increased Particle Infectivity. We pre-
viously reported that TF viruses were 2-fold more infectious than
chronic viruses from unrelated subjects (26), but two subsequent
studies failed to identify virus infectivity as a determinant of
transmission fitness (27, 28). Here, we used TZM-bl cells, which
express luciferase under the control of an HIV-1 promoter (48,
49), to determine the per-particle infectivity of CD4+ T-cell–
derived viral stocks. To limit virus infection to a single round,
we added the fusion inhibitor T1249 (50) to all cultures 12–15 h
following infection. Plotting relative light units (RLUs) per
amount of input virus (picograms of RT), we found that donor
plasma isolates exhibited a wide range of particle infectivity both
within and between individuals, whereas the infectivity of re-
cipient isolates was much less variable. Moreover, for seven
transmission pairs, recipient viruses were significantly (2- to
8-fold) more infectious than the corresponding donor viruses, with
a trend observed for the eighth pair (Fig. 1D and SI Appendix, Fig.
S4B). Higher particle infectivity relative to plasma viruses was also
observed for CVL and SEM isolates from two donors (1.8- and
3.2-fold, respectively), but not for the third donor, although in the
latter case only two CVL isolates were available for comparison
(Fig. 1D and SI Appendix, Fig. S4B). When data from all trans-
mission pairs were combined, recipient isolates were on average
3-fold more infectious (P = 0.0001) than the corresponding donor
isolates irrespective of their subtype (Fig. 1E). Donor genital se-
cretion isolates tended to be more infectious than the corre-
sponding plasma isolates, but these did not reach statistical
significance. Thus, mucosal transmission selects for viruses with
increased particle infectivity, some of which are present in genital
secretions.
Transmitted Viruses Replicate to Higher Titers. The replicative ca-
pacity of viruses can influence their reproductive ratio (R0) and
thus their ability to expand an initial infection (51). Comparing
IMCs from unrelated subjects, we previously failed to detect
differences in the growth potential of TF and chronic HIV-1
strains (26), and similar results were reported for donor and
recipient viruses from transmission pairs (27, 28). Here, we
compared the replicative capacity of limiting dilution-derived
isolates in normal donor CD4+ T cells. Using equal numbers of
particles for viral input (1 ng of RT activity), we monitored the
growth kinetics of a subset of isolates (n = 25) for 9 d by mea-
suring p24 antigen in culture supernatants every 48 h. We then
determined the area under the curve (AUC) and compared it
with p24 values measured at individual time points. This analysis
revealed a strong correlation between the AUC and p24 pro-
duction at day 7 (r = 0.99, P < 0.0001). We thus used the latter as
a measure of viral replicative capacity for all remaining isolates.
Transmitting donor isolates varied widely in their replicative ca-
pacity, and this was also true for some recipient isolates. However,
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Fig. 1. Genetic and biological characterization of
matched donor and recipient limiting dilution-
derived isolates. (A) The phylogenetic relationships
of donor (green) and recipient (brown) isolate se-
quences to donor (blue) and recipient (red) SGA-
derived plasma viral sequences are shown for the
CH596–CH455 transmission pair (maximum likeli-
hood trees for all other transmission pairs are shown
in SI Appendix, Fig. S3). Asterisks denote nodes with
100% bootstrap support (the scale bar indicates 0.01
substitutions per site). (B, D, and F) Viral Env content
(mass ratio of gp120 and RT), particle infectivity (RLU
in TZM-bl cells per picogram of RT), and replicative
capacity (p24 antigen levels in CD4+ T-cell culture
supernatants 7 d postinfection) of plasma isolates
from matched donor (D) and recipient (R) pairs (color
coded) are shown, with HIV-1 subtype classification
indicated below. Data are grouped for each trans-
mission pair, with genital secretion isolates (GS) shown
as hashed boxes. Donor D-CH472 transmitted to two
recipients R-CH378 and R-CH831. Boxes show the
interquartile range, a black bar within each box indi-
cates the geometric mean, and whiskers span the
range of the data, respectively. Asterisks indicate sig-
nificant differences (determined by unpaired t test)
between groups (*P < 0.05; **P < 0.01; ***P < 0.001;
****P < 0.0001). (C, E, and G) Hierarchical Bayesian
regression models were used to estimate the pop-
ulation-wide fold change of Env content (C), particle
infectivity (E), and replicative capacity (G) across all
transmission pairs between donor and recipient plasma
isolates (red), donor plasma and genital (Gen) secretion
isolates (blue), and clade B and C recipient isolates
(green). A dashed line indicates a fold change of 1,
indicating no effect. The estimated posterior proba-
bility distribution for each parameter is shown along
with a table summarizing the expected fold change
and the probability that the effect is <1 (analogous to
a one-sided P value).
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recipient isolates replicated on average between 1.2- and 1.7-fold
more efficiently than viruses isolated from the corresponding do-
nors (Fig. 1F and SI Appendix, Fig. S4C). These differences were
significant for seven transmission pairs, with a trend observed for
the eighth pair (Fig. 1F and SI Appendix, Fig. S4C). In contrast,
genital secretion isolates did not exhibit an increased replicative
capacity. Combining results from all transmission pairs, we found
that on average recipient isolates grew to 1.4-fold higher titers than
their corresponding donor isolates (P = 0.004), whereas no signifi-
cant differences were observed between plasma and genital secre-
tion isolates, or between recipient isolates representing subtype B
and C infections (Fig. 1G). These data indicate that mucosal
transmission selects for viruses with enhanced replicative capacity.
Transmitted Viruses Are Uniformly Resistant to Type I Interferons.
We previously reported that TF viruses are more resistant to
IFNα2 than viruses from chronically infected individuals (26, 52).
However, two subsequent studies of linked transmission pairs
failed to confirm this phenotype, with one study finding no dif-
ferences in IFNα2 resistance between transmitted and non-
transmitted viruses (27), and the other reporting transmitted
viruses being more IFNα2 sensitive (28). To resolve these dif-
ferences, we tested the IFN sensitivity of the limiting dilution-
derived isolates, but with some experimental modifications. First,
instead of testing only IFNα2, we measured the antiviral effect of a
second potent inhibitor of HIV-1, IFNβ (35, 52). Second, rather
than examining the effect of only a single IFN inhibitory dose (26–
28, 53), we determined the half-maximal inhibitory concentration
(IC50) of both IFNα2 and IFNβ for every single isolate. This was
done by treating normal donor CD4+ T cells with increasing
quantities of IFN, infecting them with equal amounts of virus, and
culturing the cells for 7 d while replenishing IFN-containing me-
dium. Virus replication was then measured for each IFN con-
centration as the amount of p24 produced at day 7 and plotted as
the percentage of viral growth in the absence of IFN, which was
set to 100% (Fig. 2 A and B). As an independent measure of IFN
resistance, we also measured viral replication at the highest IFN
dose and expressed this residual replication capacity (Vres) as the
percentage of viral growth in the absence of IFN (Fig. 2 A and B
and SI Appendix, Fig. S5 B and D).
For each transmission pair, plasma isolates from donors
exhibited a wide range of sensitivities to both IFNα2 and IFNβ,
whereas recipient isolates were much less variable as well as
uniformly more resistant to both IFNα2 and IFNβ (Fig. 2 C and
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Fig. 2. IFN resistance of matched donor and re-
cipient isolates. (A and B) Dose–response curves for
IFNα2 (A) and IFNβ (B) are shown for plasma (green)
and genital secretion (magenta) isolates of one
chronically infected donor as well as plasma isolates
of the corresponding acutely infected recipient (red)
of a representative transmission pair (CH492–CH427).
A black line indicates the half-maximal inhibitory
concentration (IC50) and a double arrow, the residual
viral replication (Vres) capacity at the highest IFN
dose. (C and E) IFNα2 (C) and IFNβ (E) concentrations
(picograms per milliliter), which resulted in 50% viral
inhibition, are shown for plasma isolates frommatched
donor (D) and recipient (R) pairs (color coded as in
Fig. 1), with HIV-1 subtype classification indicated
below. Data are grouped for each transmission pair,
with genital secretion isolates (GS) shown as hashed
boxes. Donor D-CH472 transmitted to two recipients
R-CH378 and R-CH831. Boxes show the interquartile
range, a black bar within each box indicates the geo-
metric mean, and whiskers span the range of the data,
respectively. Asterisks indicate significant differences
(determined by unpaired t test) between groups (*P <
0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001). IFN
IC50 values were determined in pooled CD4
+ T cells
from multiple donors. (D and F) Hierarchical Bayesian
regression models were used to estimate the pop-
ulation-wide fold change of IFNα2 (D) and IFNβ (F) IC50
values across all transmission pairs between donor and
recipient plasma isolates (red), donor plasma and
genital (Gen) secretion isolates (blue), and clade B
and C recipient isolates (green). A dashed vertical line
marks a fold change of 1, indicating no effect. The
estimated posterior probability distribution for each
parameter is shown along with a table summarizing
the expected fold change and the probability that the
effect is <1 (analogous to a one-sided P value).
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E). Compared with the respective donor isolates, recipient iso-
lates exhibited on average 6- to 11-fold higher IFNα2, and 15- to
71-fold higher IFNβ IC50 values (SI Appendix, Fig. S5 A and C).
Analysis of the residual replicative capacity, Vres, yielded similar
results, although the differences between donor and recipient
isolates were much more pronounced. At the highest IFNα2 dose
(5.5 pg/mL), recipient isolates retained on average 15–26% of
their replicative capacity, whereas the corresponding donor
viruses reached only 0.8–2% (SI Appendix, Fig. S5B). At the
highest IFNβ dose (0.44 pg/mL), recipient viruses retained on
average 4–13% of their replicative capacity, whereas the corre-
sponding donor isolates were either suppressed below the limits
of p24 detection or reached Vres values of 0.01–0.1% (SI Ap-
pendix, Fig. S5D). Thus, the ability of recipient isolates to rep-
licate at the highest IFN dose was 13- to 51-fold higher for
IFNα2, and 123- to 541-fold higher for IFNβ, compared with the
corresponding donor viruses (SI Appendix, Fig. S5 B and D).
Examining genital tract isolates, we found that they also exhibited
higher IFNα2 and IFNβ IC50 values than the corresponding plasma
isolates, although significance was reached only for IFNβ (P = 0.04)
(Fig. 2F). In addition, genital tract isolates exhibited higher Vres
values, but in this case, significance was reached only for IFNα2 (P =
0.008) (SI Appendix, Fig. S6B). Comparing IC50 and Vres, we found
that these values correlated strongly for donor plasma isolates
(IFNα2: r = 0.89, P < 0.0001; IFNβ: r = 0.57, P < 0.0001), but only
weakly for donor genital secretion isolates (IFNα2: r = 0.34, P <
0.05; IFNβ: r = 0.40, P < 0.01), indicating that IC50 and Vres provide
different measures of the antiviral effect of IFNs in these compart-
ments. Similarly, IC50 values for IFNα2 and IFNβ correlated only
weakly (r = 0.33, P = 0.048), indicating only a partial overlap in the
effects of the two IFN subtypes on the activation state, survival, and
IFN stimulated gene (ISG) expression levels of CD4+ T cells.
Combining data from all transmission pairs, we found that re-
cipient isolates were on average significantly more resistant to
both IFNα2 and IFNβ than the corresponding donor isolates,
exhibiting 7.8-fold (P < 0.00001) and 39-fold (P < 0.00001) higher
IC50 values, respectively (Fig. 2 D and F). Moreover, recipient
isolates had 35-fold (P < 0.00001) and 250-fold (P < 0.00001)
greater odds of replicating at the highest IFNα2 (SI Appendix, Fig.
S6B) and IFNβ (SI Appendix, Fig. S6D) doses than the great
majority of donor viruses, respectively. These differences were not
dependent on the viral subtype (Fig. 2 D and F). Thus, resistance
to type 1 IFNs is a characteristic feature of transmitted viruses.
Selection with IFNβ, but Not IFNα2, Yields Donor Isolates with a
Transmitted Virus-Like Phenotype. To search for IFN-resistant
viruses in donor plasma, we treated CD4+ T cells with high doses
of IFNα2 (4.0 pg/mL) or IFNβ (0.44 ng/mL) 24 h before virus
isolation. The rationale was to maximally up-regulate antiviral
ISGs in these target cells (without causing cell toxicity), thereby
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Fig. 3. Biological characterization of IFNα2- and
IFNβ-selected donor and recipient isolates. (A, C, E, G,
and I) IFNα2 IC50 (picograms per milliliter) (A), IFNβ
IC50 (picograms per milliliter) (C), viral Env content
(mass ratio of gp120 and RT) (E), particle infectivity
(RLU per picogram of RT) (G), and replicative capacity
in CD4+ T cells (nanograms of p24 antigen per milli-
liter) (I) values are shown for limiting dilution-de-
rived viral isolates from one representative matched
donor (D-CH492) and recipient (R-CH427) pair. In
each panel, untreated (dark green), IFNα2-selected
(light green), and IFNβ-selected (yellow) isolates from
the donor (D-492) are compared with untreated
(red), IFNα2-selected (dark pink), and IFNβ-selected
(light pink) isolates from the corresponding recipient
R-CH427. Boxes show the interquartile range, a black
bar within each box indicates the geometric mean,
and whiskers span the range of the data, respectively.
Asterisks indicate significant differences (determined
by unpaired t test) between groups (*P < 0.05; **P <
0.01; ***P < 0.001; ****P < 0.0001). Because IFN se-
lection did not alter the phenotype of recipient iso-
lates, only statistical comparisons of donor isolates to
untreated recipient isolates are shown. (B, D, F, H,
and J) Hierarchical Bayesian regression models were
used to estimate the population-wide fold change
of IFNα2 IC50 (B), IFNβ IC50 (D), Env content (F ),
particle infectivity (H), and replicative capacity in
CD4+ T cells (J) across all transmission pairs be-
tween untreated and IFNα2-selected donor isolates
(blue), untreated and IFNβ-selected donor isolates
(green), untreated and IFNα2-selected recipient
isolates (gray), and untreated and IFNβ-selected
recipient isolates (yellow). The fold change be-
tween untreated donor and recipient plasma iso-
lates (red), as in Figs. 1 and 2, is also shown for
comparison. A dashed vertical line marks a fold
change of 1, indicating no effect. The estimated
posterior probability distribution for each parameter
is shown along with a table summarizing the expec-
ted fold change and the probability that the effect is
<1 [or where indicated by an asterisk (*) the proba-
bility that the effect is >1].
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simulating, at least in part, conditions during the earliest stages
of HIV-1 infection. As a control, the same approach was used to
isolate viruses from recipient plasma. As expected, the number
of viral isolates recovered from pretreated CD4+ T cells was
lower than from untreated CD4+ T cells, especially when IFNβ
was used for selection (SI Appendix, Table S1). Thus, whereas
IFNα2 pretreatment yielded plasma isolates for all donors and
recipients, only three donors and two recipients yielded IFNβ-
preselected plasma isolates. This was as expected because the
selection dose of IFNβ was six orders of magnitude higher than
the average IFNβ IC50 value of all isolates (IFNα2 doses higher
than 5.5 pg/mL caused cell toxicity). Phylogenetic analyses of
full-length genome sequences revealed no evidence of com-
partmentalization of selected and nonselected isolates (SI Ap-
pendix, Fig. S7 and Table S2C).
IC50 determinations confirmed that donor isolates from IFN-
pretreated cells were indeed more IFN resistant than those de-
rived from untreated CD4+ T cells, whereas no changes were
observed for recipient isolates (Fig. 3). For example, IFNα2- and
IFNβ-selected plasma isolates from donor CH492 had mean
IFNα2 and IFNβ IC50 values that were 7.6-fold and 31-fold
higher than those of untreated plasma isolates (Fig. 3 A and C).
However, resistance to one IFN subtype did not always predict
resistance to the other. For donor CH492, IFNβ pretreatment
generated isolates that were also highly resistant to IFNα2 (Fig.
3A), whereas IFNα2 pretreatment generated isolates with a wide
range of IFNβ IC50 values, including some as low as untreated
isolates (Fig. 3C). When results from all donors were combined,
both IFNα2- and IFNβ-selected isolates were as resistant to IFNα2
as were untreated recipient isolates (Fig. 3B). In contrast, IFNα2-
selected isolates were 7-fold less resistant to IFNβ than IFNβ-
selected isolates, and these in turn were 2-fold less resistant than
untreated recipient isolates (Fig. 3D). Similar results were obtained
for Vres, which showed that IFNα2 selection did not generally yield
IFNβ-resistant isolates, and that IFNβ-selected isolates were less
resistant to IFNβ than untreated recipient isolates (SI Appendix,
Fig. S6). Interestingly, IFN selection did not increase the IC50
or Vres values of recipient isolates, suggesting that transmitted
viruses are already maximally resistant to both of these IFN
subtypes (Fig. 3 B and D and SI Appendix, Fig. S6 B and D).
Having generated IFNα2 or IFNβ preselected isolates, we next
examined their biological properties. For donor CH492, IFNα2
and IFNβ pretreatment resulted in isolates that packaged 2.0-
and 3.3-fold more Env than untreated isolates, respectively (Fig.
3E). However, no significant differences in Env content were
detected between treated and untreated isolates when data from
all subjects were combined (Fig. 3F). However, pretreatment
with IFNα2 and IFNβ resulted in donor isolates that exhibited
increased infectivity. This was observed for donor CH492 (Fig.
3G) as well as all donor isolates combined (Fig. 3H). IFNα2 and
IFNβ pretreatment yielded plasma isolates that were on average
2- and 2.2-fold more infectious, respectively, than isolates
obtained without selection, although neither pretreated group
was as infectious as the recipient isolates. Interestingly, IFN
pretreatment had no effect on the infectivity of recipient isolates
(Fig. 3H).
Reasoning that IFN pretreatment may favor the outgrowth of
viruses that replicated to higher titers, we compared the repli-
cative capacity of IFN-selected and -unselected donor and re-
cipient isolates. Indeed, pretreatment of CD4+ target cells with
IFNβ resulted in donor isolates that replicated more efficiently
than untreated viruses, both for CH492 (1.3-fold; Fig. 3I) and all
donor isolates combined (1.3-fold; Fig. 3J). However, this was not
observed when CD4+ T cells were pretreated with IFNα2. Sur-
prisingly, IFNα2-selected isolates replicated significantly less well,
both for donor CH492 (1.7-fold; Fig. 3I) and all donor isolates
combined (2.1-fold; Fig. 3J). For each of the seven donors, IFNα2
treatment selected isolates whose replicative capacity was much
reduced compared with untreated isolates despite higher in-
fectivity and in some cases greater amounts of packaged Env (e.g.,
CH492). These data indicate that IFNα2 and IFNβ selection can
have opposing effects on some viral properties, and that in con-
trast to previous suggestions (27), IFN resistance is not simply a
consequence of a higher replicative fitness. As expected, IFNα2
and IFNβ selection did not increase the growth potential of re-
cipient isolates (Fig. 3J). Taken together, these results indicate
that both IFNα2- and IFNβ-resistant viruses are present, albeit at
low levels, in the plasma of chronically infected individuals, and
that in vitro treatment of CD4+ T cells with IFNβ, but not IFNα2,
selects isolates that approach the phenotype of transmitted viruses
(Fig. 3 and SI Appendix, Fig. S6).
Transmitted Viruses Are More Efficiently Released from Infected
Cells. We previously reported that CD4+ T cells infected with
TF viruses released larger quantities of cell-free virions than
cultures infected with CC viruses (54). However, because only
two TF and two CC IMCs were studied, we examined this
property in a much larger number (n = 127) of matched donor
and recipient isolates. To quantify particle release from infected
CD4+ T cells, we measured the amounts of cell-free and cell-
associated p24 antigen 7 d postinfection, and used these values
to calculate the percentage of p24 that was released into
the supernatant. Consistent with our previous observations (54),
we found that donor isolates produced on average much less
cell-free virus than recipient isolates (Fig. 4), although the total
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Fig. 4. Particle release capacity of matched donor
and recipient isolates. (A) Donor and recipient iso-
lates were tested for their ability to be released from
infected CD4+ T cells. The percent of viral release was
determined as the ratio of cell-free p24 divided by
the total amount (cell associated plus cell free) of p24
7 d postinfection. Only a subset of isolates (n = 132)
was tested. Values are color coded by transmission
pair. (B) A hierarchical Bayesian regression model was
used to estimate the population-wide fold change in
the odds of release (the probability of release di-
vided by the probability of retention) of p24 be-
tween untreated and IFNα2-selected donor plasma
isolates (blue), untreated and IFNβ-selected donor
plasma isolates (green), untreated donor plasma and
genital secretion isolates (purple), untreated donor
and recipient plasma isolates (red), untreated and
IFNα2-selected recipient isolates (gray), and un-
treated and IFNβ-selected recipient isolates (yel-
low). A dashed vertical line marks a fold change of
1, indicating no effect. The estimated posterior probability distribution for each parameter is shown along with a table summarizing the expected fold
change and the probability that the effect is <1 (analogous to a one-sided P value).
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amount of p24 in these cultures was comparable. Plasma and
genital secretion isolates from chronically infected donors re-
leased on average 31% and 38% of their total p24, respectively,
whereas recipient isolates released 65%. In addition, IFN-selected
isolates released more p24 than unselected donor isolates, al-
though this effect was less pronounced for IFNα2 (42%) than
for IFNβ (64%). Combining results from all isolates, the odds
of p24 antigen being released from CD4+ T-cell cultures in-
fected with IFNα2- and IFNβ-selected donor isolates were
1.6-fold and 3.8-fold higher, respectively, than from cultures
infected with untreated donor isolates, and the odds of release
were even higher (4.2-fold) for untreated recipient isolates
(Fig. 4B). In contrast, no differences were observed for donor
genital secretion isolates as well as for IFN-treated and un-
treated recipient isolates (Fig. 4B). Thus, mucosal transmission
selects for viruses with a significantly enhanced particle release
capacity, suggesting that the production of cell-free virions is
important in the transmission process.
Discussion
An effective AIDS vaccine will need to prevent acquisition of
HIV-1 at mucosal surfaces (5). In this context, it is critical to
know whether transmitted viruses possess unique biological
properties that predispose them to establish new infections more
efficiently. This is a controversial topic, because some studies
have reported TF-specific traits (22, 24, 26, 52, 55–57), whereas
others have failed to confirm these results (27, 28, 53, 58, 59).
Some of these discrepancies are likely due to the fact that most
previous analyses did not compare HIV-1 strains from trans-
mission pairs. Using a more rigorous approach, two recent
studies characterized viruses from matched donors and recipi-
ents, but failed to identify viral properties that were indicative
of enhanced transmission fitness (27, 28). These findings led to
the prevailing view that HIV-1 transmission is a stochastic
process in which any reasonably fit virus has the potential of
crossing the mucosa.
Both transmission pair studies characterized only very few
donor and recipient viruses, using either infectious molecular
clones (27) or peripheral blood mononuclear cell (PBMC)-
derived bulk cultures (28). Reasoning that this approach had
likely led to erroneous conclusions, we used limiting dilution
isolation to generate a much larger number of donor and re-
cipient viruses for phenotypic comparisons. We also used
plasma rather than PBMCs for virus isolation to preclude the
characterization of archived HIV-1 strains, generated genital
secretion isolates for a subset of donors, and examined viral
properties, such as virion release and resistance to IFNβ, which
have not been previously characterized. Finally, we rendered
the CD4+ T cells used for virus isolation more resistant to
infection by treating them with high doses of type 1 IFNs to
simulate host innate defenses that may be operative during the
earliest stages of infection. We found that both recipient and
in vitro IFN-selected donor isolates were more infectious,
replicated to higher titers, were released from infected cells
more efficiently, and were much more resistant to both IFNα2
and IFNβ than the great majority of unselected donor isolates
(Figs. 1–4). Thus, it seems clear that these viral properties
collectively contribute to transmission fitness.
To visualize the biological properties examined for all virus
isolates (particle Env content, infectivity, replicative capacity,
IFN IC50, and Vres values) in combination, we conducted a
principal component analysis (Fig. 5 A and B). This approach
revealed two major groups, one that contained all plasma and
genital secretion isolates from chronically infected donors, and
another that included all plasma isolates from acutely infected
recipients (Fig. 5A). The fact that there was no overlap between
these groups indicates that transmitted viruses are phenotypically
distinct. This conclusion was confirmed when IFN-treated iso-
lates were plotted on the same principal components (Fig. 5B).
Whereas most IFNα2-selected donor isolates grouped within the
untreated donor cluster, most IFNβ-selected donor isolates
overlapped the cluster of recipient viruses (Fig. 5B).
To quantify these relationships, we calculated the distance
between each virus and its pair-matched recipient average of the
first two principal components (Fig. 5C). As expected, untreated
and IFN-treated recipient isolates were the closest to the re-
cipient average, exhibiting only minimal variation. In contrast,
untreated donor plasma and genital secretion isolates as well as
IFNα2-selected donor isolates were most distant from the aver-
age position of their respective recipient isolates and exhibited a
wide distribution of distances. Interestingly, IFNβ-selected donor
isolates were much closer to their recipient isolate average,
consistent with IFNβ selection yielding a transmitted virus-like
phenotype. We also examined the accuracy with which an isolate
could be predicted to be derived from either a donor or a re-
cipient on the basis of the seven biological properties examined
(Fig. 5D). This analysis showed that IFN IC50 and Vres values
predicted donor and recipient isolates with near 100% accuracy,
indicating that resistance to type 1 IFNs is the most distinguishing
characteristic of transmitted viruses.
If IFN resistance represents such a discerning feature, why did
previous transmission pair studies miss this property? As shown
in Fig. 2, chronic viruses exhibit a wide range of IFN IC50 values,
indicating that random selection of just two such viruses per
transmitting donor as reported by Deymier et al. (27) may not
reveal donor/recipient differences. Moreover, measuring viral
inhibition in response to a single IFN dose (26–28, 53) is likely
less accurate than a formal IC50 determination. It should also be
noted that the resistance of HIV-1 to IFNs is not constant during
the course of infection. IFN resistance declines rapidly within the
first 6 mo (52, 57), but then increases again when subjects
progress toward AIDS (52, 60, 61). Thus, depending on when
during the course of infection a virus is transmitted to another
person, donor viruses may be more or less IFN resistant. For
example, viruses from donors who transmit during acute HIV-1
infection or immediately following treatment interruption as
described by Oberle et al. (28) would be expected to exhibit
much higher levels of IFN resistance than viruses from subjects
who transmit during asymptomatic chronic infection. In addition,
PBMC cultures may reactivate latent viruses, which would be
expected to exhibit IFN resistance levels consistent with their
entry into the latent pool.
None of the previous transmission pair studies analyzed viral
resistance to IFNβ, which produced the most pronounced donor/
recipient differences. Indeed, the 39-fold higher IFNβ IC50 val-
ues of recipient isolates (Fig. 2F) is likely a gross underestimate,
because many donor viruses were already more than 50%
inhibited at the lowest IFNβ dose (Fig. 2B). This finding explains
why the donor/recipient differences for IFNβ Vres values are so
much higher than the corresponding IC50 values and why these
differences are not observed for IFNα2 (Fig. 2F and SI Appendix,
Fig. S5D). Whereas both IC50 and Vres values provide an in-
dicator of IFN resistance, they seem to describe only partially
overlapping biological effects. For example, the strong correla-
tion of both IFNα2 and IFNβ IC50 and Vres values for donor
plasma isolates likely indicates restriction by an IFN dose-driven
increase in ISG activity. In contrast, the lack of a similarly strong
correlation for donor genital secretion isolates suggests that
some of these viruses are restricted by ISGs whose inhibitory
activity is not IFN dose dependent. In addition, Vres may be a
more relevant indicator of IFN resistance during the acute phase
of infection when IFN levels are particularly high in the mucosa,
whereas IC50 may be a more appropriate measure of systemic
immune activation during later stages of infection. Future studies
will need to determine the full range of IFNα2 and IFNβ IC50
and Vres values in HIV-1–infected subjects over time.
Not all viral properties studied contributed, or contributed
equally, to HIV-1 transmission fitness. For example, virion-
associated Env content, although previously identified as a char-
acteristic feature of TF viruses (26), did not differentiate donor
and recipient isolates (Figs. 1C and 5D). Nonetheless, in half of
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the transmission pairs studied, recipient isolates packaged sig-
nificantly more Env than the respective donor viruses (Fig. 1B),
suggesting that increased Env content may increase transmission
fitness under certain circumstances. Similarly, particle infectivity
and replicative capacity were significantly increased in most, but
not all, recipient isolates. The successful transmission of viruses
lacking these properties suggests that they are not absolutely
required and/or that their absence can be compensated by other
factors. In contrast, enhanced resistance to type I IFNs was ob-
served for every single recipient isolate, indicating that the ability
to counteract these innate immune responses is essential for
successful mucosal transmission.
The need to overcome innate defenses is also exemplified by
the fact that recipient and IFNβ-selected donor isolates pro-
duced much higher levels of cell-free virus than the corre-
sponding untreated donor isolates (Fig. 4). Type 1 IFNs induce
tetherin, which prevents the release of virus particles from the
plasma membrane of infected cells. HIV-1 counteracts tetherin
using its Vpu protein, which binds tetherin and prevents its ex-
pression on the cell surface (62–64). However, TF Vpu proteins
do not seem to counteract tetherin more effectively than the Vpu
protein of chronic viruses (65). Moreover, TF-infected CD4+ T
cells were shown to produce more cell-free virions even in the
absence of Vpu (54). Although we have not mapped the genomic
region(s) responsible for the significantly enhanced virion re-
lease capacity of recipient isolates, it is unlikely that Vpu alone
is responsible. In fact, several isolates that differed significantly
in their particle release function encoded identical vpu genes
(SI Appendix, Fig. S7). Thus, it seems clear that other as-yet-
unknown factors must be responsible for the increased particle
release function of recipient (and IFNβ-selected donor) isolates,
which may be critical to enhance virus spread in the mucosa
during the first rounds of replication when extracellular IFN
levels are particularly high.
In summary, we have identified resistance to type 1 IFNs, in
particular IFNβ, as a key determinant of HIV-1 transmission
fitness. This observation is consistent with previous studies
showing that innate responses in the mucosa immediately fol-
lowing infection are inducing a potent antiviral state through the
up-regulation of ISGs, many of which have anti–HIV-1 activity
(63, 64, 66–73). All IFN subtypes signal through the same het-
erodimeric receptor (30), but differences in receptor binding
and/or downstream signal transduction pathways are thought to
be responsible for IFN subtype-specific biological effects (74–
77). IFNβ has been reported to bind the IFN receptor (IFNAR)
with the highest affinity (76) and ligates the IFNAR1 chain in an
IFNAR2-independent manner, resulting in the expression of a
distinct set of genes (78). Either of these properties could explain
its greater potency in placing selection on the transmitted virus
pool. Nonetheless, IFNβ selection did not fully recapitulate the
biological properties of recipient isolates despite the extremely
high dose that was used to treat the target cells (Figs. 3D and 5 B
and C and SI Appendix, Fig. S6D). These results indicate that
additional factors, possibly including IFNα2 and/or other IFN
subtypes, shape the transmitted founder phenotype. Because
there are a total of 13 IFNα subtypes as well as other type 1 IFNs
such as IFNω, some of which inhibit HIV-1 even more potently
in vitro and in animal models (79–81), it will be critical to
evaluate to what extent they contribute alone, or in combination,
to the HIV-1 transmission bottleneck.
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Fig. 5. Phenotypic properties distinguishing do-
nor and recipient isolates. (A) Principal compo-
nent analysis was used to visualize properties that
were determined for all viral isolates (Env con-
tent, particle infectivity, replicative capacity,
IFNα2 IC50, IFNβ IC50, IFNα2 Vres, and IFNβ Vres) in
combination. The positions of untreated donor
plasma (green), donor genital secretion (purple),
and recipient plasma (red) isolates are shown on
the first two components. Length and direction of
arrows show how each variable contributes to the
two axes. The minimum spanning ellipses that
contain all data points for each group are shown
in corresponding colors. (B) To visualize the effect
of IFN selection, IFNα2-selected (green), and
IFNβ-selected (yellow) donor isolates are plotted
together with IFNα2-selected (dark pink) and
IFNβ-selected (light pink) recipient isolates on
the same principal components as in A. Minimum
spanning ellipses encompassing the untreated
donor plasma isolates (green), donor genital se-
cretion isolates (purple), and untreated recipient
plasma isolates (red) as shown in A were retained.
(C ) To quantify the groupings apparent in A and
B, we calculated the distance of the first two
principal components for each isolate to the av-
erage position of the corresponding untreated
recipient isolates for that transmission pair. Iso-
lates are color coded by transmission pairs and
grouped as in A and B. (D) The accuracy with which
the seven viral properties predicted whether an
isolate came from a donor or recipient was mea-
sured using receiver operating characteristic
curves. Each line indicates the trade-off between
true and false positive rates as a threshold is
moved through the range of the data. Shading
indicates the 95% confidence interval of the
true positive rate. The dashed line indicates the
expected performance of a predictor with no relationship to donor–recipient status. A line that reaches a true positive rate of 100% with a 0% false
positive rate indicates that there is perfect separation between donor and recipient isolates.
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Materials and Methods
Study Subjects. Transmission pairs were identified in the context of the Center
for HIV/AIDS Vaccine Immunology (CHAVI-001) acute infection cohort (82).
Plasma samples were obtained from eight acutely infected subjects (recipi-
ents) and their transmission partners (donors), with epidemiological linkage
confirmed by viral sequence analysis (SI Appendix, Fig. S1). For a subset of
donors, cervicovaginal lavage and semen samples were also available. Rel-
evant epidemiological information is listed in SI Appendix, Table S1. Written
informed consent was obtained from each subject and the study was ap-
proved by the institutional review boards of the University of Pennsylvania
and Duke University.
Generation of Limiting Dilution HIV-1 Isolates. Plasma samples as well as cell-
depleted genital secretions were end-point diluted and used to infect 1 × 106
positively selected, activated CD4+ T cells (pooled from multiple donors) in
24-well plates. Cultures were maintained for 20 d, tested for p24 antigen
(26), and virus positive wells were expanded in normal donor CD4+ T cells for
an additional 10 d. The resulting (one time expanded) viral stocks were used
for all genetic and biological analyses.
Isolate Sequencing. Viral RNA was extracted from isolate stocks, reverse
transcribed, and the resulting cDNAwas used to amplify overlapping 5′ and 3′
genome halves in separate PCR reactions (14, 26). Amplicons were se-
quenced using an Illumina NGS platform, and paired-end reads were as-
sembled to generate a sample-specific reference sequence. Viral reads were
mapped to this reference, and the extent of genetic diversity was examined
for each position along the alignment. Isolates that exhibited more than
15% diversity at any one position were judged to contain more than one
variant and removed from further analysis.
Phylogenetic Analyses. Nucleotide sequences were aligned using CLUSTALW
v2 (83), with ambiguous regions removed. Maximum likelihood trees with
bootstrap support (1,000 replicates) were constructed using PhyML v3.1 (84)
with evolutionary models selected using jModelTest v2.1.4 (85) or for larger
datasets, RAxML using a GTRGAMMA model (86). The gsi was used to cal-
culate the degree of phylogenetic association of sequences (47).
Env Content and Particle Infectivity. Particle-associated Env content was
measured as described (26), with minor modifications (SI Appendix). Virion
infectivity was measured using the TZM-bl reporter cell line as described
(26), except for adding the fusion inhibitor T1249 (0.01 mg/mL) to prevent
multiple rounds of infection.
Replicative Capacity and IFN Resistance. To determine the IFNα2 and IFNβ
concentrations required to inhibit virus replication by 50% (IC50), activated
CD4+ T cells were left untreated or cultured in the presence of increasing
amounts of IFNα2 (0.00074 pg/mL–5.5 pg/mL) or IFNβ (0.000067 pg/mL–0.44
pg/mL) for 24 h, infected with equal amounts of virus (1 ng of RT), and
cultured for 7 d, while replenishing IFN-containing medium every 48 h. Virus
replication was measured as the amount of p24 produced at day 7 and
plotted for each IFN concentration as the percentage of viral growth in the
absence of IFN. Residual virus replication (Vres) was measured at the highest
IFNα and IFNβ concentrations and expressed as the percentage of replication
in the absence of IFN. Replication in the untreated cells was used to de-
termine the replicative capacity of viral isolates. Experiments were con-
ducted in pooled CD4+ T cells from multiple normal subjects (SI Appendix
provides details).
Isolation of IFN-Resistant Viruses. To generate IFN-resistant viruses, pooled
CD4+ T cells were treated with high (but nontoxic) doses of IFNα2 (4.0 pg/mL)
or IFNβ (44 ng/mL) for 24 h before the addition of end-point diluted donor
and recipient plasma. Limiting dilution isolates were generated and main-
tained as described above.
Virion Release. Pooled CD4+ T cells were infected with equal amounts of virus
and maintained for 7 d. To quantify particle release, both cell-free and cell-
associated amounts of p24 antigen levels were measured, and the per-
centage of p24 that was released into the supernatant was calculated.
Statistical Analyses. For intrapair comparisons, P values were derived using
Welch’s unequal variance t test to compare log-transformed values. Pop-
ulation-wide fold changes of viral properties were estimated using hierar-
chical Bayesian regression models (87), which accounted for (i) nested
measurements within a transmission pair, (ii) multiple transmissions from a
single donor, (iii) heteroscedasticity between groups, and (iv) censored data
where measurements were less than a given value. These models assumed
that observations were normally distributed, with mean and variance drawn
from population-level distributions (SI Appendix, SI Materials and Methods).
Posterior probability distributions were estimated using Markov chain
Monte Carlo sampling, implemented in Stan v2.12.0 (88) and R v3.3.1 (89).
The models were used to estimate the fold change of log-transformed
functional data (or logit-transformed proportional data) between donor
and recipient plasma isolates as well as donor plasma and genital secretion
isolates, along with effects of HIV-1 subtype and IFNα2 or IFNβ selection. Fold
change for viral properties was based on the estimated posterior mean, and
probability values were calculated from the estimated cumulative posterior
probability for a fold change of <1 (or >1 in the case of a posterior mean of
<1) for the population-level parameters. Principal component and receiver
operating characteristic analysis (90) were performed using R v3.3.1.
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